Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The FDA aims to make a decision by April 8, 2026
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
HYMPAVZI’s safety profile was generally favorable
76 of 180 long COVID-associated genes also linked to ME
MRI is particularly valuable in pediatric care due to its non-invasive nature
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated